Preliminary results of a phase 1 study in healthy subjects administered inclacumab, a fully human IgG4 anti-P-selectin monoclonal antibody in development for treatment of sickle cell disease

Authors
Category Primary study
JournalHemaSphere
Year 2022
This article has no abstract
Epistemonikos ID: e38a39d696a1b645565f5a5dee94f31c505fe098
First added on: Feb 13, 2025